Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics is expected to continue to grow and improve patient care and reduce healthcare costs through its focus on high-growth MedTech products, strong balance sheet and cash flow, and diverse product offerings across its three segments. While there may be challenges in the blood center segment, the company's overall performance, as rated by analysts, is projected to be OUTPERFORM with a rising price target. Haemonetics Corporation has a positive outlook due to its focus on high-growth MedTech products, strong balance sheet and cash flow, and diverse product offerings across its three segments. The company saw growth in its plasma business and remains focused on reducing healthcare costs and improving patient care. Challenges in the Blood Center segment may be a potential concern, but analysts are projecting overall OUTPERFORM performance for the company, with a rising price target.

Haemonetics is expected to experience a 1% to 4% reported revenue decline and 7% to 10% organic growth in FY/26, with a 26% to 27% adjusted operating margin and $4.93 non-GAAP EPS. While the company has shown some improvements in profitability, this growth is still unimpressive and does not justify an investment in the stock, especially with the expected decline in overall revenue and the highly competitive nature of its blood center segment. Additionally, the company's increase in free cash flow is not significant enough to change the negative outlook, as it is still below the previous guidance.